SP1 and cardiac hypertrophy: Indeed, we found that the inhibition of SP1 and EGR1, which are newly found TFs with fetal chromatin accessibility patterns in patients, markedly repressed cardiac hypertrophy in HCM mice and thus provided potential drug targets for HCM treatment.